Scarica l'app Stockscreener
4.89
5.62%
0.26
Precedente Chiudi:
$4.63
Aprire:
$4.68
Volume 24 ore:
1.26M
Relative Volume:
1.05
Capitalizzazione di mercato:
$177.60M
Reddito:
$317.00K
Utile/perdita netta:
$-53.47M
Rapporto P/E:
-2.5873
EPS:
-1.89
Flusso di cassa netto:
$-49.31M
1 W Prestazione:
+30.05%
1M Prestazione:
+15.88%
6M Prestazione:
+177.84%
1 anno Prestazione:
+365.71%
Intervallo 1D:
$4.5022
$4.98
Intervallo di 1 settimana:
$3.25
$4.98
Portata 52W:
$1.01
$4.98
Immuneering Corp Stock (IMRX) Company Profile
Nome
Immuneering Corp
Settore
Industria
Telefono
617-500-8080
Indirizzo
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Confronta IMRX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
4.89 | 127.12M | 317.00K | -53.47M | -49.31M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-13 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2024-03-15 | Downgrade | Jefferies | Buy → Hold |
| 2024-03-15 | Reiterato | Needham | Buy |
| 2024-03-15 | Downgrade | TD Cowen | Outperform → Market Perform |
| 2023-12-01 | Iniziato | Needham | Buy |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-04-19 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-04-19 | Aggiornamento | Morgan Stanley | Underweight → Equal-Weight |
| 2023-03-30 | Iniziato | Mizuho | Neutral |
| 2023-02-03 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2022-07-08 | Iniziato | Chardan Capital Markets | Buy |
| 2022-04-01 | Iniziato | Oppenheimer | Outperform |
| 2022-01-07 | Iniziato | Piper Sandler | Overweight |
Mostra tutto
Immuneering Corp Borsa (IMRX) Ultime notizie
Volatility clustering patterns for Immuneering CorporationWeekly Trade Summary & AI Enhanced Trading Signals - Newser
Should you hold or exit Immuneering Corporation nowJuly 2025 Momentum & Low Risk Investment Opportunities - Newser
Understanding Immuneering Corporation’s price movementJuly 2025 EndofMonth & Reliable Volume Spike Trade Alerts - Newser
Mizuho Securities Maintains Buy Rating on Immuneering with $10 Price Target - AInvest
Live market analysis of Immuneering CorporationJuly 2025 Fed Impact & Free Community Supported Trade Ideas - Newser
Immuneering Corporation stock prediction for this week2025 Year in Review & Proven Capital Preservation Tips - Newser
Pattern recognition hints at Immuneering Corporation upsideEarnings Overview Summary & Fast Exit and Entry Trade Guides - Newser
Published on: 2025-08-19 23:23:02 - Newser
What machine learning models say about Immuneering CorporationJuly 2025 Momentum & Verified Momentum Watchlists - Newser
Immuneering Corporation stock trendline breakdown2025 Dividend Review & Community Shared Stock Ideas - Newser
Leading vs lagging indicators on Immuneering Corporation performanceWeekly Trading Summary & Free Weekly Watchlist of Top Performers - Newser
Does Immuneering Corporation show high probability of reboundTrade Analysis Report & Proven Capital Preservation Methods - Newser
Immuneering Corporation’s volatility index tracking explainedInflation Watch & Real-Time Chart Pattern Alerts - Newser
Published on: 2025-08-18 00:12:21 - Newser
Is this a good reentry point in Immuneering Corporation2025 Short Interest & Verified Short-Term Trading Plans - Newser
Order flow analysis tools used on Immuneering Corporation2025 Market Sentiment & Free Technical Confirmation Trade Alerts - Newser
Immuneering’s (IMRX) “Buy” Rating Reiterated at Chardan Capital - Defense World
Using Python tools to backtest Immuneering Corporation strategiesIndex Update & Low Risk High Reward Ideas - Newser
Can Immuneering Corporation maintain its current growth rateJuly 2025 PostEarnings & Free Weekly Watchlist of Top Performers - sundaytimes.kr
Applying chart zones and confluence areas to Immuneering CorporationWeekly Profit Summary & Fast Moving Stock Watchlists - Newser
Immuneering's 22% Surge: A Technical Rebound or Sector Catalyst? - AInvest
IMRX’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Immuneering Corp Q2 2025 Earnings: EPS Beats Estimate, Reports $14.4M Net Loss, Highlights Robust Cash Position and Clinical Advancements - AInvest
Immuneering Corp. Reports Strong Trial Results and Patent Win - TipRanks
Immuneering Reports Q2 GAAP EPS of -$0.40, Cash Reserves at $26.4 Million. - AInvest
Immuneering Reports Second Quarter 2025 Financial Results and Provides Business Updates - The Manila Times
Analysts Set Immuneering Corporation (NASDAQ:IMRX) Price Target at $13.25 - Defense World
Can swing trading help recover from Immuneering Corporation lossesRisk-Managed Swing Setup and Signal Analysis - Newser
Is Immuneering Corporation showing signs of accumulationFree Trend Analysis for Safer Trades - Newser
Is Immuneering Corporation stock entering bullish territoryGold Moves & Safe Capital Investment Plans - Newser
Quant Tools Rank Immuneering Corporation as High Risk High RewardStep-by-Step Trade Signal Implementation Guide Ready - metal.it
Is it the right time to buy Immuneering Corporation stockExtraordinary earning power - Jammu Links News
What drives Immuneering Corporation stock priceGet high-impact stock recommendations now - Jammu Links News
How many analysts rate Immuneering Corporation as a “Buy”Build a diversified portfolio for maximum returns - Jammu Links News
What are Immuneering Corporation company’s key revenue driversExceptional stock performance - Jammu Links News
Multi asset correlation models including Immuneering CorporationFree Multi-Bagger Potential Stock Forecast Tools - Newser
How does Immuneering Corporation compare to its industry peersStock Strategy Entry Points Backed By Experts - Jammu Links News
Real time breakdown of Immuneering Corporation stock performanceStrong Buy Opportunity with Volume Support - Newser
Immuneering reports Q1 EPS (42c), consensus (58c) - TipRanks
How Efficient Is Immuneering Corporation at Controlling Operating CostsFree Trade Timing Strategy With Technical Data - Newser
Immuneering Corporation’s Price Action Aligns with Quant SignalsConsistent Income Focused Trade List Analyzed - metal.it
Published on: 2025-07-28 06:27:12 - Jammu Links News
What makes Immuneering Corporation stock price move sharplyProven High Yield Signals - metal.it
How strong is Immuneering Corporation company’s balance sheetBreakout profit opportunities - Jammu Links News
Immuneering Corp Azioni (IMRX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Immuneering Corp Azioni (IMRX) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| HAUSMAN DIANA | Director |
Jul 02 '25 |
Buy |
3.60 |
2,500 |
8,989 |
2,500 |
| Neufeld Leah R | CHIEF PEOPLE OFFICER |
Jul 02 '25 |
Buy |
3.57 |
700 |
2,499 |
10,729 |
| Zeskind Benjamin J. | PRESIDENT AND CEO |
Jul 02 '25 |
Buy |
3.53 |
7,015 |
24,792 |
2,312,852 |
| Zeskind Benjamin J. | PRESIDENT AND CEO |
Jul 01 '25 |
Buy |
3.38 |
2,985 |
10,087 |
2,305,837 |
| Schall Thomas J. | Director |
Jun 27 '25 |
Buy |
3.66 |
9,500 |
34,788 |
52,885 |
| Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER |
Jun 20 '25 |
Buy |
2.70 |
7,415 |
20,020 |
353,311 |
| Hall Brett Matthew | CHIEF SCIENTIFIC OFFICER |
Jun 23 '25 |
Buy |
2.43 |
6,007 |
14,596 |
359,318 |
| Brakewood Harold Eugene | Chief Business Officer |
Jun 20 '25 |
Buy |
2.53 |
1,900 |
4,804 |
5,800 |
| Feinberg Peter | Director |
Jun 18 '25 |
Buy |
2.53 |
25,000 |
63,188 |
136,766 |
| Zeskind Benjamin J. | PRESIDENT AND CEO |
Jun 18 '25 |
Buy |
2.39 |
21,000 |
50,144 |
2,302,852 |
0.94%
1.72%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):